Edwards’s Sapien Trial Raises Bias Question Among FDA Staff

The way Edwards Lifesciences Corp. selected and categorized patients in a trial for its Sapien heart valve may have been biased, making an evaluation of the device as an alternative to open-heart surgery difficult, U.S. Food and Drug Administration staff said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.